Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Mar. 29, 2024
shares
| |
| Trading Arrangements, by Individual | |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Dana T. Aftab [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | Dana T. Aftab, our Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer, an officer for purposes of Section 16 of the Exchange Act, entered into a pre-arranged stock trading plan on May 25, 2023, which was subsequently modified on February 27, 2024. As modified, Dr. Aftab’s trading plan provides for the sale of up to 194,656 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between May 30, 2024 and September 30, 2025. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities. |
| Name | Dana T. Aftab |
| Title | Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | May 25, 2023 |
| Arrangement Duration | 488 days |
| Aggregate Available | 194,656 |
| Jeffrey J. Hessekiel [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | Jeffrey J. Hessekiel, our Executive Vice President, General Counsel and Secretary, an officer for purposes of Section 16 of the Exchange Act, entered into a pre-arranged stock trading plan on February 28, 2024. Mr. Hessekiel’s trading plan provides for the sale of up to 200,000 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between May 29, 2024 and December 31, 2024. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities. |
| Name | Jeffrey J. Hessekiel |
| Title | Executive Vice President, General Counsel and Secretary |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | February 28, 2024 |
| Arrangement Duration | 216 days |
| Aggregate Available | 200,000 |
| Jack L Wyszomierski [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | Jack L Wyszomierski, a member of our Board of Directors, entered into a pre-arranged stock trading plan on February 12, 2024. Mr. Wyszomierski’s trading plan provides for the sale of up to 19,973 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between May 13, 2024 and June 12, 2024. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities. |
| Name | Jack L Wyszomierski |
| Title | Board of Directors |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | February 12, 2024 |
| Arrangement Duration | 30 days |
| Aggregate Available | 19,973 |